4.6 Article

Well-defined labile diselenide-centered poly(epsilon-caprolactone)-based micelles for activated intracellular drug release

Journal

JOURNAL OF MATERIALS CHEMISTRY B
Volume 4, Issue 29, Pages 5059-5067

Publisher

ROYAL SOC CHEMISTRY
DOI: 10.1039/c6tb01040g

Keywords

-

Funding

  1. National Natural Science Foundation of China [21274039]
  2. Shanghai Pujiang Program [14PJD014]
  3. 111 Project [B14018]
  4. Specialized Research Fund for the Doctoral Program of Higher Education [20130074110007]
  5. Basic Research Key Program Project of Commission of Science and Technology of Shanghai [12JC1403000, 12JC1403100]

Ask authors/readers for more resources

Well-defined diselenide-centered biodegradable tri-block copolymers methoxyl poly(ethylene glycol)-b-poly(epsilon-caprolactone)-b-methoxyl poly(ethylene glycol) (mPEG-PCL-Se)(2) were precisely synthesized by the combination of ring opening polymerization using di(1-hydroxyethylene) diselenide as a new initiator and a facile coupling reaction. The amphiphilic block copolymers enabled the formation of self-assembled micelles which revealed an excellent reductive response to glutathione (GSH) due to the unique reduction-responsive cleavage of the diselenide bond. Such GSH response ensured an enhanced release of anticancer drugs (DOX) from the micelles in simulative tumor microenvironments; moreover, the drug release could be changed to some extent through fine-tuning the chemical composition of the copolymers. Flow cytometry and confocal laser scanning microscopy (CLSM) measurements confirmed that the DOX-loaded micelles could be efficiently taken up by oral squamous carcinoma (HN30) cells and DOX was released into the nuclei of cancer cells following 4 h of incubation. The cell viability assays showed the diselenide-containing polymers were nontoxic up to a tested concentration (400 mu g mL(-1)), while the DOX-loaded micelles exhibited an evident inhibition toward HN30 cells. Therefore, the reduction-labile biodegradable (mPEG-PCL-Se)(2) may offer an alternative platform for tumor-targeting therapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available